Koyfin Home > Directory > Health Care > Revance Therapeutics > Enterprise Value

Revance Therapeutics Enterprise Value Chart (RVNC)

Revance Therapeutics annual/quarterly Enterprise Value from 2014 to 2020.
  • Revance Therapeutics Enterprise Value for the quarter ending September 09, 2020 was $1,825m a -4.88% decrease of -89m year over year
  • Revance Therapeutics Enterprise Value for the last 12 months ending September 09, 2020 was $1,825m a -4.88% decrease of -89m year over year
  • Revance Therapeutics Annual Enterprise Value for 2020 was $1,825m a 0.00% decrease of 0m from 2019
  • Revance Therapeutics Annual Enterprise Value for 2020 was $1,825m a -7.91% decrease of -144m from 2019
  • Revance Therapeutics Annual Enterprise Value for 2020 was $1,969m a 2.81% increase of 55m from 2019
Other Valuation Metrics:
  • Revance Therapeutics Market Cap for the quarter ending March 03, 2018 was $1,131m a 29.36% increase of 332m year over year
  • Revance Therapeutics Price / Book for the quarter ending March 03, 2018 was 4.18 a -6.42% decrease of -0.27 year over year
View Chart On Koyfin

Quarterly RVNC Enterprise Value Data

09/2020$1,825m
09/2020$1,825m
09/2020$1,969m
09/2020$1,914m
09/2020$1,644m
09/2020$1,564m
09/2020$1,539m
09/2020$1,607m
09/2020$1,502m
09/2020$1,496m

Annual RVNC Enterprise Value Data

2020$1,825m
2020$1,825m
2020$1,969m
2020$1,914m
2020$1,644m
2020$1,564m
2020$1,539m
2020$1,607m
2020$1,502m
2020$1,496m